Patents Examined by David A. Montanari
  • Patent number: 12031154
    Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: July 9, 2024
    Assignee: President and Fellows of Harvard College
    Inventors: Torsten B. Meissner, Leonardo M. R. Ferreira, Jack L. Strominger, Chad A Cowan
  • Patent number: 12031155
    Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: July 9, 2024
    Assignee: President and Fellows of Harvard College
    Inventors: Torsten B. Meissner, Leonardo M. R. Ferreira, Jack L. Strominger, Chad A. Cowan
  • Patent number: 12031152
    Abstract: Provided herein are nutrient media formulations and engineered growth factors, and methods thereof, useful for the production of slaughter-free meat.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: July 9, 2024
    Assignee: UPSIDE FOODS, INC.
    Inventors: Kalle Lukyan Johnson, Patricia R. Benton, Cameron Gentry Copeland, Sukhdeep Singh Dhadwar, Meri Teresa Firpo, Marie Elizabeth Gibbons, Stephen K. Hsu, Robert Sierra, Kevin John Kayser
  • Patent number: 12018286
    Abstract: Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 25, 2024
    Assignee: The Cleveland Clinic Foundation
    Inventors: Oliver Wessely, Uyen Wessely, Jan Jensen, Michael Bukys
  • Patent number: 12018280
    Abstract: The disclosure provides a method of freezing an aggregate of pluripotent stem cell-derived cardiomyocytes, comprising: (i) immersing an aggregate of pluripotent stem cell-derived cardiomyocytes in a cryoprotective solution; and (ii) freezing the aggregate immersed in the cryoprotective solution. The disclosure also provides a frozen aggregate of pluripotent stem cell-derived cardiomyocytes frozen by the method.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: June 25, 2024
    Assignee: KYOTO UNIVERSITY
    Inventor: Itsunari Minami
  • Patent number: 12004493
    Abstract: An animal model (e.g., mouse) and method of use, and cell culture assay method, for characterizing or screening a test compound for its effect on late onset Alzheimer's disease (LOAD). The test compound may be used as a therapeutic agent for treatment of Alzheimer's disease (AD). The AD animal model may be haploinsufficient for Shugoshin 1 (Sgo1) gene, or may comprise a genetic modification enabling modulation of Sgo1 expression in the brain of the animal when exposed to an Sgo1 expression-modulating compound, such as tamoxifen. After the test compound is administered to the animal model, the presence or amount of an AD biomarker is assessed or measured.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: June 11, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Hiroshi Yamada, Chinthalapally Rao
  • Patent number: 11997994
    Abstract: This disclosure relates to genetically modified animals and cells with humanized light chain immunoglobulin locus and/or humanized heavy chain immunoglobulin locus. In one aspect, the endogenous light chain immunoglobulin locus comprises a limit number of human IGKV genes and human IGKJ genes.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: June 4, 2024
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yabo Zhang, Hui Lu, Huizhen Zhao, Jiawei Yao, Yi Yang, Yuelei Shen
  • Patent number: 11987813
    Abstract: Human pluripotent stem cells (hPSCs) are promising cell source to produce therapeutic endocrine cells for diabetes treatment. A gel solution made by decellularized tissue-specific extracellular matrix (dpECM) significantly promotes three-dimensional (3D) islet-like organogenesis during induced hPSC differentiation into endocrine lineages. Islet organoids are self-organized even in a two-dimensional (2D) culture mode. Cells derived from hPSCs differentiated on such ECM coated substrates exhibit similar cellular composition to native pancreatic islets. These cells express islet signature markers insulin, PDX-1, C-peptide, MafA, glucagon, somatostatin, and pancreatic polypeptide, and secrete more insulin in response to glucose level compared to a traditional matrix substrate (Matrigel). The dpECM facilitates generating more C-peptide+/glucagon? cells rather than C-peptide+/glucagon+ cells. Remarkably, dpECM also facilitated intra-organoid vascularity by generating endothelial cells and pericytes.
    Type: Grant
    Filed: September 7, 2020
    Date of Patent: May 21, 2024
    Assignee: The Research Foundation for The Sate University of New York
    Inventors: Sha Jin, Kaiming Ye, Huanjing Bi
  • Patent number: 11982673
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 14, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11981929
    Abstract: The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells of a mature phenotype. The resulting pancreatic endocrine cells express single hormonal insulin, PDX1, NKX6.1, and MAFA. In one or more differentiation stages, culturing may be carried out in a culture vessel at the air-liquid interface.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: May 14, 2024
    Assignee: Janssen Biotech, Inc.
    Inventor: Alireza Rezania
  • Patent number: 11982672
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: May 14, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11959091
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 16, 2024
    Assignee: Cellectis
    Inventors: Philippe Duchateau, André Choulika, Laurent Poirot
  • Patent number: 11952591
    Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 9, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Sebastian Rieck, Alireza Rezania
  • Patent number: 11904001
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 20, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 11896622
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 13, 2024
    Assignee: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Patent number: 11889821
    Abstract: The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 6, 2024
    Assignee: TRIANNI, INC.
    Inventors: Matthias Wabl, Bao Duong, Werner Mueller
  • Patent number: 11890304
    Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: February 6, 2024
    Assignee: Janssen Biotech, Inc.
    Inventor: Jean Xu
  • Patent number: 11885807
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 30, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11885806
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: January 30, 2024
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Paul Maciocia
  • Patent number: 11884924
    Abstract: The present disclosure provides compositions of matter, methods and instruments for nucleic acid-guided nickase/reverse transcriptase fusion enzyme editing of nucleic acids in live mammalian cells.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: January 30, 2024
    Assignee: Inscripta, Inc.
    Inventors: Brian Chaikind, Aamir Mir